Physician profile
Esther Lynn Fields
NPI 1366616203
$4,749.40
in general payments reported to CMS, 2019-2025
34 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $762 · 2021: $623 · 2022: $484 · 2023: $572 · 2024: $650 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,636.45 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.75 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $289.06 | 2019-2025 | Arikayce |
| Astrazeneca Pharmaceuticals Lp | $259.95 | 2019-2024 | Airsupra |
| Pfizer INC. | $239.63 | 2023-2025 | |
| United Therapeutics Corporation | $233.44 | 2023-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $210.02 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $193.08 | 2019-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $135.85 | 2019-2023 | Cresemba |
| Electromed, INC. | $130.84 | 2019-2024 | Smartvest |
| Philips North America LLC | $107.22 | 2019-2025 | Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $88.31 | 2023-2024 | Dupixent, Libtayo |
| Paratek Pharmaceuticals, INC. | $80.44 | 2020-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $74.23 | 2019 | |
| Inogen, INC. | $62.24 | 2023-2025 | Inogen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.39 | 2021-2024 | Glassia |
| Ani Pharmaceuticals, INC. | $50.62 | 2024-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $46.99 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $42.82 | 2020-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Allergan, INC. | $39.14 | 2019-2020 | |
| Melinta Therapeutics, LLC | $37.51 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.95 | 2022 | |
| Viatris Specialty LLC | $26.31 | 2025 | Yupelri |
| Olympus America INC. | $23.28 | 2023 | Spin Thoracic Navigation System, 120v, 60hz |
| Genentech USA, INC. | $22.96 | 2019 | |
| Tactile Systems Technology INC | $21.12 | 2024 | Flexitouch Plus, Entre Plus |
| Genzyme Corporation | $20.36 | 2021 | |
| Covis Pharma Gmbh | $20.32 | 2022 | |
| Amgen INC. | $18.78 | 2025 | Tezspire |
| Hospira, INC. | $18.40 | 2025 | |
| Bolton Medical INC | $17.05 | 2019 | |
| Circassia INC. | $15.54 | 2019 | |
| Merck Sharp & Dohme LLC | $12.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.